Early rheumatoid arthritis: therapeutic strategies.

The early stage of rheumatoid arthritis (RA) is a unique and critical phase of disease which is often characterized by profound inflammation, severe symptomatology and a high likelihood of radiological progression. Decisions on treatment strategies need to be taken before irreversible damage and functional deterioration occur. There is evidence that early intervention with disease-modifying drugs may reduce functional deterioration and improve long-term outcome. Stable genetic markers and rheumatoid factor are useful in predicting disease severity and thus in identifying those patients who require early aggressive therapy. The acute phase response (APR) is a valuable marker of disease activity and catabolism in RA, and suppression of the APR improves outcome. The use of early aggressive therapy to suppress disease efficiently in patients with a poor prognosis should improve the long-term morbidity and mortality associated with RA.

[1]  R. Eastell,et al.  Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. , 1994, Annals of the rheumatic diseases.

[2]  Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. , 1993, British journal of rheumatology.

[3]  R. Holder,et al.  Generalised bone loss in patients with early rheumatoid arthritis , 1994, The Lancet.

[4]  J. Bell,et al.  Limited heterogeneity of the HLA class II contribution to susceptibility to rheumatoid arthritis is suggested by positive associations with HLA-DR4, DR1 and DRw10. , 1991, British journal of rheumatology.

[5]  P. Bacon,et al.  Progression of radiological changes in rheumatoid arthritis. , 1984, Annals of the rheumatic diseases.

[6]  V. Wright,et al.  C-reactive protein in the serial assessment of disease activity in rheumatoid arthritis. , 1984, Scandinavian journal of rheumatology.

[7]  Paul Wordsworth,et al.  Genetically determined factors as predictors of radiological change in patients with early symmetrical arthritis. , 1992, BMJ.

[8]  S. Holbeck,et al.  HLA-DR4-Associated Disease: Oligonucleotide Probes Identify Specific Class II Susceptibility Genes in Type I Diabetes and Rheumatoid Arthritis , 1989 .

[9]  J. Bell,et al.  HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. McConkey,et al.  Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. , 1977, British medical journal.

[11]  P. Dawes,et al.  Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. , 1986, British journal of rheumatology.

[12]  T. Pincus,et al.  Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. , 1988, Journal of clinical epidemiology.

[13]  P. Stastny Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. , 1978, The New England journal of medicine.

[14]  P. Gregersen,et al.  The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. , 1987, Arthritis and rheumatism.

[15]  G. Rinaldi,et al.  High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. , 1992, Arthritis and rheumatism.